An Experts' Forum in Tokyo and Singapore on DDR and PARP inhibition

DDR and PARPi Expert Forums were held with international faculty in Tokyo and Singapore during January 2020.

Learn about the role of PARP inhibitors in clinical practice and targeting DDR, including:

Mechanism of Action of PARP inhibition and targeting DDR
Clinical profile of PARP inhibitors and their benefit in ovarian and breast cancer
Appropriate patient selection for PARP inhibition
Future DDR and PARP inhibition

Prof. Keiichi Fujiwara has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Abbvie, AstraZeneca, Clovis, Eisai, MSD, Ono, Pfizer and Takeda.

Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Artios Pharma Ltd.

Dr Shinji Ohno has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Chugai, Eisai, Eli Lilly, KyowaHakko, Kirin and Taiho

Dr Rebecca Dent has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Eisai, Genentech, Lilly, Merck, Novartis, Pfizer and Roche.

Prof. Charlie Gourley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro.

DOWNLOAD SLIDES TOKYO

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Prof. Keiichi Fujiwara

Prof. Simon Boulton

Dr Shinji Ohno

Dr Rebecca Dent

Prof. Charlie Gourley

Overview

Experts

Downloads

Learn about the role of PARP inhibitors in clinical practice and targeting DDR, including:

Mechanism of Action of PARP inhibition and targeting DDR

Clinical profile of PARP inhibitors and their benefit in ovarian and breast cancer

Appropriate patient selection for PARP inhibition

Future DDR and PARP inhibition

Prof. Keiichi Fujiwara

Prof. Simon Boulton

Dr Shinji Ohno

Dr Rebecca Dent

Prof. Charlie Gourley

Programme summary

I agree that this educational programme:

Other programmes of interest

The evolving role of liquid biopsy in biomarker testing

Experts

Advanced renal cell carcinoma: Managing a long-term durable response

Experts

Endorsed by

Episode

1

of 1

Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer

Experts

Endorsed by

Oncogene-addicted NSCLC: Highlights from ASCO 2024

Experts

Upper and lower GI cancer update from ASCO 2024

Experts

Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Experts

An Experts’ Forum in Tokyo and Singapore on DDR and PARP inhibition

Prof. Keiichi Fujiwara

Prof. Simon Boulton

Dr Shinji Ohno

Dr Rebecca Dent

Prof. Charlie Gourley

Publication Date

Overview

Experts

Downloads

Learn about the role of PARP inhibitors in clinical practice and targeting DDR, including:

Mechanism of Action of PARP inhibition and targeting DDR

Clinical profile of PARP inhibitors and their benefit in ovarian and breast cancer

Appropriate patient selection for PARP inhibition

Future DDR and PARP inhibition

<img src="https://dpgqxyxbc4u03.cloudfront.net/cms/wp-content/uploads/2022/06/GJKH7-Keiichi-Fujiwara-150x150.jpg" alt="Prof. Keiichi Fujiwara"> Prof. Keiichi Fujiwara Gynaecologic Oncologist Saitama Medical University International Medical Center Japan (JP)

Prof. Keiichi Fujiwara

Disclosures

<img src="https://dpgqxyxbc4u03.cloudfront.net/cms/wp-content/uploads/2022/06/E5Wtm-simon-boulton-150x150.jpg" alt="Prof. Simon Boulton"> Prof. Simon Boulton Senior Scientist Francis Crick Institute United Kingdom (GB)

Prof. Simon Boulton

Disclosures

<img src="https://dpgqxyxbc4u03.cloudfront.net/cms/wp-content/uploads/2022/06/bYOZ5-Shinji-Ohno-150x150.jpeg" alt="Dr Shinji Ohno"> Dr Shinji Ohno Medical Oncologist Cancer Institute Hospital of JFCR Japan (JP)

Dr Shinji Ohno

Disclosures

<img src="https://dpgqxyxbc4u03.cloudfront.net/cms/wp-content/uploads/2022/06/vJdUP-Rebecca-Dent-150x150.jpg" alt="Dr Rebecca Dent"> Dr Rebecca Dent Medical Oncologist National Cancer Center Singapore Singapore (SG)

Dr Rebecca Dent

Disclosures

<img src="https://dpgqxyxbc4u03.cloudfront.net/cms/wp-content/uploads/2022/06/B2QgH-Charlie-Gourley-2-150x150.jpg" alt="Prof. Charlie Gourley"> Prof. Charlie Gourley Medical Oncologist CRUK Edinburgh Centre, Nicola Murray Centre for Ovarian Cancer Research United Kingdom (GB)

Prof. Charlie Gourley

Disclosures

Programme summary

Share this programme

I agree that this educational programme:

Other programmes of interest

The evolving role of liquid biopsy in biomarker testing

Experts

Advanced renal cell carcinoma: Managing a long-term durable response

Experts

Endorsed by

Episode

1

of 1

Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer

Experts

Endorsed by

Oncogene-addicted NSCLC: Highlights from ASCO 2024

Experts

Upper and lower GI cancer update from ASCO 2024

Experts

Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Experts